XML 21 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 6,515,028 $ 5,794,272
Short-term investment securities 748,290 6,847,270
Interest receivable 10,083 58,285
Accounts receivable 466,159 330,001
Prepaid expenses and other current assets 327,775 392,236
Total current assets 8,067,335 13,422,064
Non-current assets:    
Operating lease right-of-use asset, net 141,439 0
Investment in Alphazyme 0 284,709
Other assets 10,462 6,045
Total assets 8,219,236 13,712,818
Current liabilities:    
Accounts payable 656,445 1,276,313
Accrued expenses 1,057,164 955,081
Deferred research and development obligations 490,113 40,743
Deferred license revenue, current portion 0 176,471
Operating lease liability, current portion 48,059 0
Total current liabilities 2,251,781 2,448,608
Deferred license revenue, net of current portion 0 176,471
Operating lease liability, net of current portion 88,870 0
Total liabilities 2,340,651 2,625,079
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding 0 0
Authorized shares - 100,000,000; issued shares - 41,064,563 and 40,816,602, outstanding shares - 28,811,061 and 28,563,100 as of December 31, 2023 and 2022, respectively 41,065 40,817
Additional paid-in capital 105,044,756 103,458,697
Treasury stock, shares held at cost - 12,253,502 (18,929,915) (18,929,915)
Accumulated deficit (80,277,321) (73,481,860)
Total stockholders’ equity 5,878,585 11,087,739
Total liabilities and stockholders’ equity $ 8,219,236 $ 13,712,818